Tuesday, September 16, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

Israeli co Nectin Therapeutics raises $25m

by Globes correspondent
November 30, 2022
in Business
Reading Time: 2 mins read
A A
0
Home Business
Share on FacebookShare on Twitter

Israeli biotechnology company Nectin Therapeutics has announced that it has completed a $25 million Series A financing round led by IBF and Peregrine Ventures, with participation from aMoon Fund and other existing investors.

Jerusalem-based Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments. The company also announced today dosing of the first patient in its Phase I clinical trial of NTX1088, the company’s first-in-class PVR (CD155) blocker, in cancer patients with locally advanced and metastatic solid tumors. The trial is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) with an investment from the Cancer Focus Fund, LP. The trial will include up to 90 patients treated with NTX1088 as a monotherapy and in combination with a PD-1 blocker.

The Series A funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs).

NTX1088 is a first-in-class high-affinity monoclonal antibody directed against PVR, a transmembrane protein expressed on cancer cells and associated with resistance to PD-1 and PD-L1 immune checkpoint inhibitors.

Nectin cofounder and CSO Dr. Pini Tsukerman said, “PVR blockade by NTX1088, with its first-in-class differentiated mechanism of action, has demonstrated compelling preclinical anti-tumor activity both as a monotherapy and in combination with other cancer immunotherapies. Importantly, NTX1088 has potent activity in ICI refractive models where TIGIT or PD-1 blockade has failed to show a benefit.”

Nectin CEO Fabian Tenenbaum added, “Nectin has developed a highly innovative pipeline that has the potential to fundamentally overcome the limitations of existing IO therapies, delivering new treatment options for patients suffering from difficult-to-treat cancers, and we look forward to the results of the Phase 1 clinical trial of NTX1088.”

Published by Globes, Israel business news – en.globes.co.il – on November 30, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.




Source link

Tags: 25MIsraeliNectinraisesTherapeutics
Previous Post

New Fortress: Valuation May Get Reset Shortly (NASDAQ:NFE)

Next Post

Recession Playbook – The Reformed Broker

Related Posts

RBI issues guidelines for payment aggregators, licence now mandatory

RBI issues guidelines for payment aggregators, licence now mandatory

by zee business
September 16, 2025
0

The Reserve Financial institution of India (RBI) has made it obligatory for fee aggregators to acquire prior licences to be...

ITR Filing Deadline Extended Till Sept 16 Amid Complaints Of Glitches On E-Filing Portal

ITR Filing Deadline Extended Till Sept 16 Amid Complaints Of Glitches On E-Filing Portal

by NDTV Profit Desk
September 15, 2025
0

The due date for submitting of Revenue Tax Returns for Evaluation Yr 2025-26 has been prolonged by one other day,...

Israeli drone camera co NextVision raising 0m

Israeli drone camera co NextVision raising $400m

by Netanel Ariel
September 15, 2025
0

After its share worth has risen 272% over the previous 12 months and 1,765% over the previous three years,...

Naidu offers farmers incentive to reduce use of urea

Naidu offers farmers incentive to reduce use of urea

by Euro Times
September 15, 2025
0

Andhra Pradesh Chief Minister Chandrababu Naidu addresses the fourth district Collectors’ Convention on the Secretariat in Amaravati on Monday. |...

Commodity Radar: Buy on dips as gold consolidates ahead of Fed. 5 tech tools to sharpen your trades

Commodity Radar: Buy on dips as gold consolidates ahead of Fed. 5 tech tools to sharpen your trades

by Shivendra Kumar
September 15, 2025
0

Gold was buying and selling with delicate weak spot on Monday amid revenue reserving forward of the US Federal Reserve's...

Phoenix to finance four Enav urban renewal projects

Phoenix to finance four Enav urban renewal projects

by Globes correspondent
September 14, 2025
0

Actual property firm Enav has signed a financing settlement with insurance coverage firm Phoenix Monetary (TASE: PHOE). Underneath the...

Next Post
Recession Playbook – The Reformed Broker

Recession Playbook - The Reformed Broker

How to Read Your Property Insurance Policy

How to Read Your Property Insurance Policy

Politics And The Markets 09/16/25

Politics And The Markets 09/16/25

September 16, 2025
RBI issues guidelines for payment aggregators, licence now mandatory

RBI issues guidelines for payment aggregators, licence now mandatory

September 16, 2025
Monday Night Football: How to Watch Buccaneers vs. Texans, Chargers vs. Raiders Tonight

Monday Night Football: How to Watch Buccaneers vs. Texans, Chargers vs. Raiders Tonight

September 16, 2025
5 Ways Soaking Almonds Could Make Them Healthier

5 Ways Soaking Almonds Could Make Them Healthier

September 16, 2025
Trump says US struck another Venezuelan drug vessel, killing three | News

Trump says US struck another Venezuelan drug vessel, killing three | News

September 15, 2025
How to install a smart light switch or dimmer

How to install a smart light switch or dimmer

September 15, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Politics And The Markets 09/16/25

RBI issues guidelines for payment aggregators, licence now mandatory

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In